If you’re over 75 and reading about a GLP-1 study, it’s fair to ask: were people my age actually in it?
Sometimes they were, but the number can vary a great deal from one trial to another. Being represented in one trial is different from having every question answered. The medicine, the participants’ health and what researchers measured all matter.
A closer look at two sets of studies
In certain weight-reduction and maintenance trials of Wegovy injections, 23 people receiving semaglutide were age 75 or older, about 1% of those receiving the medicine. A small group can provide some information, but it leaves more uncertainty about less common experiences and the variety of health circumstances in that age range.
A separate cardiovascular outcomes trial included more older participants: 703 people receiving the injection were at least 75, about 8% of that treatment group. That study involved adults with established cardiovascular disease and overweight or obesity. It answered a specific heart-health question, so its population should be kept in mind.
Those figures describe semaglutide in these particular studies. They are not counts for every GLP-1 medicine or every trial.
Why does the size of the group matter?
When only a few participants share a characteristic, it is harder to estimate outcomes for that group with precision. A trial average can be useful while still leaving unanswered questions about someone with a history of falls, several medicines or difficulty eating enough.
Age alone doesn’t describe a person’s health. Two people who are both 78 may have very different activity levels, medical histories, priorities and support at home.
Researchers also need to make sure they measure things that matter to older adults: strength, balance, daily function, nutrition and quality of life, alongside weight and side effects.
What about bone health?
In the cardiovascular trial, more hip and pelvis fractures were reported among semaglutide-treated participants age 75 or older than among placebo-treated participants in that age group. That is a specific finding from one trial, not a statement that every older person will experience a fracture or that every related medicine has the same result.
It does make fracture history and fall risk useful topics for a treatment discussion. If you’ve had a fracture, osteoporosis, a recent fall or trouble with balance, share that information with your care team.
Frailty is another research question
Researchers also examined a frailty score in a later analysis of the cardiovascular trial. The analysis included participants across different levels of the score; it was not a study only of people over 75.
That work adds to the picture, but it does not replace an individual assessment or settle every question about nutrition and day-to-day function. A useful follow-up may include asking how you feel getting out of a chair, preparing meals or doing the activities you want to keep doing.
It can help to name an activity you want to protect before treatment begins. Perhaps it is carrying a basket of laundry, visiting a neighbor or walking your dog. Revisit that goal at follow-up, especially if your appetite, energy or balance has changed.
Questions to bring to an appointment
Ask what treatment is intended to help with and how you’ll know whether it is working for you. You might also discuss your current medicines, eating routine, ability to use the prescribed device, recent weight changes and any help you want from a family member or caregiver.
If appetite is so low that regular meals are difficult, bring it up. A dietitian or clinician can help consider a plan that fits your health and preferences.
Our guide to GLP-1 treatment after 65 offers more ideas for those conversations. The goal is a plan that accounts for your life, not just the average participant in a study.